Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients

Annals of Oncology

Volumn 11, Issue SUPPL. 1, 2000, Pages

  Milpied, N ^a,n   Vasseur, B ^b   Parquet, N ^b   Garnier, J L ^c   Antoine, C ^o   Quartier, P ^d   Carret, A S ^e   Bouscary, D ^o   Faye, A ^f   Bourbigot, B ^g   Reguerre, Y ^h   Stoppa, A M ⁱ   Bourquard, P ^j   Hurault De Ligny, B ^k   Dubief, F ^l   Mathieu Boue, A ^o   Leblond, V ^m  

^a HÔTEL DIEU   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e CHU NANCY BRABOIS   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g SERVICE DE RHUMATOLOGIE   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j Centre Hospitalier La Beauchee   (France)

^k CHU Clemenceau   (France)

^l Axens   (France)

^m PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁿ NANTES UNIVERSITY HOSPITAL   (France)

^o NONE

more..

Author keywords

Chimeric anti CD20 monoclonal antibody; Disorder; Post transplant B lymphoproliferative

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MALE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL;

EID: 0033997255     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_1.S113     Document Type: Conference Paper

References (15)

1. Frizzera G, Hanto DW, Gail-Peczalska KJ et al. Polymorphic diffuse B cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262-79.
2. Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developping under ciclosporine steroid therapy. Lancet 1984; 1: 583-7.
3. Grant D. The international intestinal transplant registry: Current results of intestinal transplantation. Lancet 1996; 347: 1801-3.
4. Zutter MM, Martin PJ, Sale GE et al. Epstein Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-9.
5. Ho M, Jaffe R. Miller G et al. The frequency of Epstein Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719-27.
6. Shapiro RS, McClain K, Frizzera G et al. Epstein Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-43.
7. Garrett TJ, Chadburn A, Barr ML et al. Posttransplanlation lymphoproliferative disorders treated with cyclophosphamide doxorubicin vineristine prednisone chemotherapy. Cancer 1993; 72: 2782-5.
8. Shapiro RS, Chauvenet A, McGuire W et al. Treatment of B-cell lymphoproliferative disorders with interferon-alfa and intravenous gamma globulin. N Engl J Med 1988; 318: 1334 (Letter).
9. Pirsch JD, Stratta RJ, Sollinger HW et al. Treatment of severe Epstein Barr virus induced lymphoproliferative syndrome with ganciclovir: Two cases after solid organ transplantation. Am J Med 1989; 86: 241-4.
10. Papadopoulos EB, Ladanyi M, Emmanuel D et al. Infusion of donor leukocytes to treat Epstein Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-91.
11. Rooney CM, Smith CA, Ng Cyg et al. Use of gene modified virus specific T lymphocytes to control Epstein-Barr virus related lymphoproliferation. Lancet 1995; 345: 9-13.
12. Fischer A, Blanche S, Le Bidois J et al. Anti B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451-6.
13. Benkerrou M, Jais JP, Leblond V et al. Anti B-cell monoclonal antibody treatment of severe post transplant B lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998; 92: 3137-47.
14. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
15. Haque T, Amlot PL, Helling N et al. Reconstitution of EBV-Specific T-cell immunity in solid organ transplant recipients. J Immunol 1998; 160: 6204-9.